Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T56418 | Target Info | |||
Target Name | ALK tyrosine kinase receptor (ALK) | ||||
Synonyms |
CD246; Anaplastic lymphoma kinase
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | ALK | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Proto-oncogene c-Ros (ROS1) | Successful Target | ||||
UniProt ID | ROS1_HUMAN | |||||
Gene Name | ROS1 | |||||
Synonyms |
c-Ros receptor tyrosine kinase; Receptor tyrosine kinase c-ros oncogene 1; ROS; Proto-oncogene tyrosine-protein kinase ROS; Proto-oncogene c-Ros-1; MCF3
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | Ki < 0.02 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | Ki < 0.02 nM | [1] | ||
3 | Ceritinib | Drug Info | Ki = 0.4 nM | [4] | ||
4 | Crizotinib | Drug Info | Ki = 0.6 nM | [4] | ||
5 | AP26113 | Drug Info | IC50 = 1.9 nM | [9] | ||
6 | Brigatinib | Drug Info | IC50 = 1.9 nM | [10] | ||
7 | Entrectinib | Drug Info | IC50 = 5 nM | [11] | ||
8 | Repotrectinib | Drug Info | IC50 = 8.4 nM | [3] | ||
Co-Target Name | Tropomyosin-related kinase A (TrkA) | Successful Target | ||||
UniProt ID | NTRK1_HUMAN | |||||
Gene Name | NTRK1 | |||||
Synonyms |
gp140trk; Tyrosine kinase receptor A; Tyrosine kinase receptor; Trk-A; TRKA; TRK1-transforming tyrosine kinase protein; TRK1 transforming tyrosinekinase protein; TRK; P140-TrkA; Neurotrophic tyrosine kinase receptor type 1; NGF-trk receptor type A; MTC; High affinity nerve growth factor receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 = 0.22 nM | Click to Show More | [2] | |
2 | Repotrectinib | Drug Info | IC50 = 0.4 nM | [3] | ||
3 | Crizotinib | Drug Info | IC50 < 1 nM | [7] | ||
4 | TSR-011 | Drug Info | IC50 < 3 nM | [3] | ||
5 | PF-06463922 | Drug Info | IC50 = 24 nM | [1] | ||
6 | Lorlatinib | Drug Info | IC50 = 24 nM | [1] | ||
Co-Target Name | Proto-oncogene c-Met (MET) | Successful Target | ||||
UniProt ID | MET_HUMAN | |||||
Gene Name | MET | |||||
Synonyms |
Tyrosine-protein kinase Met; Scatter factor receptor; SF receptor; Met proto-oncogene tyrosine kinase; Hepatocyte growth factor receptor; HGF/SF receptor; HGF-SF receptor; HGF receptor; C-met; C-Met receptor tyrosine kinase
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 = 0.51 nM | Click to Show More | [5] | |
2 | X-396 | Drug Info | IC50 = 0.69 nM | [6] | ||
3 | Ensartinib | Drug Info | IC50 = 0.74 nM | [5] | ||
4 | Ceritinib | Drug Info | IC50 = 271 nM | [18] | ||
Co-Target Name | Tyrosine-protein kinase UFO (AXL) | Successful Target | ||||
UniProt ID | UFO_HUMAN | |||||
Gene Name | AXL | |||||
Synonyms |
UFO; Tyrosine-protein kinase receptor UFO; AXL oncogene
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 < 1 nM | [7] | ||
Co-Target Name | Epidermal growth factor receptor (EGFR) | Successful Target | ||||
UniProt ID | EGFR_HUMAN | |||||
Gene Name | EGFR | |||||
Synonyms |
Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB
Click to Show/Hide
|
|||||
Representative Drug(s) | Brigatinib | Drug Info | IC50 = 1 nM | Click to Show More | [8] | |
2 | Ceritinib | Drug Info | IC50 = 19 nM | [14] | ||
3 | Crizotinib | Drug Info | IC50 = 681 nM | [19] | ||
Co-Target Name | LCK tyrosine protein kinase (LCK) | Successful Target | ||||
UniProt ID | LCK_HUMAN | |||||
Gene Name | LCK | |||||
Synonyms |
p56-LCK; Tyrosine-protein kinase Lck; T cell-specific protein-tyrosine kinase; Proto-oncogene tyrosine-protein kinase LCK; Proto-oncogene Lck; Protein YT16; Lymphocyte cell-specific protein-tyrosine kinase; Leukocyte C-terminal Src kinase; LSK; LCK p59-Fyn; LCK Protooncogene Syn
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 < 1 nM | Click to Show More | [7] | |
2 | Ceritinib | Drug Info | IC50 = 560 nM | [13] | ||
3 | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | BDNF/NT-3 growth factors receptor (TrkB) | Successful Target | ||||
UniProt ID | NTRK2_HUMAN | |||||
Gene Name | NTRK2 | |||||
Synonyms |
Tropomyosin-related kinase B; TrkB tyrosine kinase; Trk-B; TRKB; Neurotrophic tyrosine kinase receptor type 2; GP145-TrkB
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 = 2 nM | Click to Show More | [7] | |
2 | TSR-011 | Drug Info | IC50 < 3 nM | [3] | ||
3 | Entrectinib | Drug Info | IC50 = 3 nM | [11] | ||
4 | PF-06463922 | Drug Info | Ki = 23 nM | [4] | ||
5 | Lorlatinib | Drug Info | Ki = 23 nM | [4] | ||
Co-Target Name | Fms-like tyrosine kinase 3 (FLT-3) | Successful Target | ||||
UniProt ID | FLT3_HUMAN | |||||
Gene Name | FLT3 | |||||
Synonyms |
Stem cell tyrosine kinase 1; STK1; STK-1; Receptor-type tyrosine-protein kinase FLT3; Fetal liver kinase-2; FLT-3; FLK2; FLK-2; FL cytokine receptor; CD135
Click to Show/Hide
|
|||||
Representative Drug(s) | Brigatinib | Drug Info | IC50 = 2.1 nM | Click to Show More | [10] | |
2 | Ceritinib | Drug Info | IC50 = 60 nM | [13] | ||
3 | Entrectinib | Drug Info | IC50 = 164 nM | [11] | ||
4 | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | NT-3 growth factor receptor (TrkC) | Successful Target | ||||
UniProt ID | NTRK3_HUMAN | |||||
Gene Name | NTRK3 | |||||
Synonyms |
TrkC tyrosine kinase; Trk-C; TRKC; Neurotrophic tyrosine kinase receptor type 3; NT3 growth factor receptor; GP145TrkC; GP145-TrkC
Click to Show/Hide
|
|||||
Representative Drug(s) | TSR-011 | Drug Info | IC50 < 3 nM | Click to Show More | [3] | |
2 | Entrectinib | Drug Info | IC50 = 3 nM | [11] | ||
3 | PF-06463922 | Drug Info | IC50 = 46 nM | [1] | ||
4 | Lorlatinib | Drug Info | IC50 = 46 nM | [1] | ||
Co-Target Name | Insulin-like growth factor I receptor (IGF1R) | Successful Target | ||||
UniProt ID | IGF1R_HUMAN | |||||
Gene Name | IGF1R | |||||
Synonyms |
Type 1 insulin-like growth factor receptor; Insulin-like growth factor 1 receptor; IGF-IR; IGF-I receptor; IGF-1R; IGF-1 receptor; CD221 antigen; CD221
Click to Show/Hide
|
|||||
Representative Drug(s) | AP26113 | Drug Info | IC50 = 3.2 nM | Click to Show More | [10] | |
2 | Ceritinib | Drug Info | IC50 = 8 nM | [13] | ||
3 | Brigatinib | Drug Info | IC50 = 24.9 nM | [10] | ||
4 | Entrectinib | Drug Info | IC50 = 122 nM | [11] | ||
5 | Crizotinib | Drug Info | IC50 = 143 nM | [10] | ||
Co-Target Name | Proto-oncogene c-Ret (RET) | Successful Target | ||||
UniProt ID | RET_HUMAN | |||||
Gene Name | RET | |||||
Synonyms |
RET51; RET receptor tyrosine kinase; RET mutant Y791F; RET mutant V804M; RET mutant V804L; RET mutant S891A; RET mutant M918T; RET mutant G691S; Proto-oncogene tyrosine-protein kinase receptor Ret; PTC; Cadherin family member 12; CDHR16; CDHF12; C-ret
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 4.8 nM | Click to Show More | [12] | ||
2 | Entrectinib | Drug Info | IC50 = 393 nM | [11] | ||
3 | Ceritinib | Drug Info | IC50 = 400 nM | [13] | ||
Co-Target Name | Proto-oncogene c-Src (SRC) | Successful Target | ||||
UniProt ID | SRC_HUMAN | |||||
Gene Name | SRC | |||||
Synonyms |
pp60c-src; Tyrosine kinase (pp60(src)); Src tyrosine kinase; SRC1; Proto-oncogene tyrosine-protein kinase Src; Pp60(src); P60-Src; C-src TK; C-Src
Click to Show/Hide
|
|||||
Representative Drug(s) | Repotrectinib | Drug Info | IC50 = 5.3 nM | Click to Show More | [5] | |
2 | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | Insulin receptor (INSR) | Successful Target | ||||
UniProt ID | INSR_HUMAN | |||||
Gene Name | INSR | |||||
Synonyms |
IR; CD220 antigen; CD220
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | IC50 = 7 nM | Click to Show More | [13] | |
2 | AP26113 | Drug Info | IC50 = 100 nM | [10] | ||
3 | Crizotinib | Drug Info | IC50 = 102 nM | [7] | ||
4 | Brigatinib | Drug Info | IC50 = 196 nM | [10] | ||
5 | Entrectinib | Drug Info | IC50 = 209 nM | [11] | ||
6 | TSR-011 | Drug Info | IC50 = 231 nM | [17] | ||
Co-Target Name | Tyrosine-protein kinase ABL1 (ABL) | Successful Target | ||||
UniProt ID | ABL1_HUMAN | |||||
Gene Name | ABL1 | |||||
Synonyms |
p150; Proto-oncogene tyrosine-protein kinase ABL1; Proto-oncogene c-Abl; JTK7; C-ABL; Abl; Abelson tyrosine-protein kinase 1; Abelson murine leukemia viral oncogene homolog 1
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 = 24 nM | Click to Show More | [7] | |
2 | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Janus kinase 2 (JAK-2) | Successful Target | ||||
UniProt ID | JAK2_HUMAN | |||||
Gene Name | JAK2 | |||||
Synonyms |
Tyrosine-protein kinase JAK2
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 = 27 nM | Click to Show More | [15] | |
2 | Entrectinib | Drug Info | IC50 = 40 nM | [11] | ||
3 | Ceritinib | Drug Info | IC50 = 610 nM | [13] | ||
Co-Target Name | Multidrug resistance protein 1 (ABCB1) | Clinical trial Target | ||||
UniProt ID | MDR1_HUMAN | |||||
Gene Name | ABCB1 | |||||
Synonyms |
PGY1; P-glycoprotein 1; MDR1; CD243 antigen; CD243; ATP-binding cassette sub-family B member 1
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | EC50 = 89 nM | [16] | ||
Co-Target Name | Janus kinase 1 (JAK-1) | Successful Target | ||||
UniProt ID | JAK1_HUMAN | |||||
Gene Name | JAK1 | |||||
Synonyms |
Tyrosine-protein kinase JAK1; JAK1B; JAK1A
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 = 112 nM | Click to Show More | [11] | |
2 | Crizotinib | Drug Info | IC50 = 563 nM | [15] | ||
Co-Target Name | Fibroblast growth factor receptor 2 (FGFR2) | Successful Target | ||||
UniProt ID | FGFR2_HUMAN | |||||
Gene Name | FGFR2 | |||||
Synonyms |
Keratinocyte growth factor receptor 2; Keratinocyte growth factor receptor; KSAM; KGFR; K-sam; FGFR-2; FGF-2 receptor; CD332; BEK
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | IC50 = 260 nM | [13] | ||
Co-Target Name | Janus kinase 3 (JAK-3) | Successful Target | ||||
UniProt ID | JAK3_HUMAN | |||||
Gene Name | JAK3 | |||||
Synonyms |
Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 = 349 nM | [11] | ||
Co-Target Name | Erbb2 tyrosine kinase receptor (HER2) | Successful Target | ||||
UniProt ID | ERBB2_HUMAN | |||||
Gene Name | ERBB2 | |||||
Synonyms |
p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | Fibroblast growth factor receptor 1 (FGFR1) | Successful Target | ||||
UniProt ID | FGFR1_HUMAN | |||||
Gene Name | FGFR1 | |||||
Synonyms |
c-fgr; bFGF-R-1; bFGF-R; N-sam; HBGFR; Fms-like tyrosine kinase 2; FLT2; FLT-2; FLG; FGFR-1; FGFBR; CEK; CD331 antigen; CD331; Basic fibroblast growth factor receptor 1; BFGFR
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | Click to Show More | [20] | |
2 | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Vascular endothelial growth factor receptor 2 (KDR) | Successful Target | ||||
UniProt ID | VGFR2_HUMAN | |||||
Gene Name | KDR | |||||
Synonyms |
VEGFR2; VEGFR-2; VEGF-2 receptor; Protein-tyrosine kinase receptor flk-1; Kinase insert domain receptor; Fetal liver kinase 1; FLK1; FLK-1; CD309
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | Click to Show More | [20] | |
2 | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Tyrosine-protein kinase Kit (KIT) | Successful Target | ||||
UniProt ID | KIT_HUMAN | |||||
Gene Name | KIT | |||||
Synonyms |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; p145 c-kit; Proto-oncogene tyrosine-protein kinase Kit; Proto-oncogene c-Kit; Piebald trait protein; PBT; Mast/stem cell growth factor receptor Kit; CD117 antigen; CD117; C-kit
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Platelet-derived growth factor receptor alpha (PDGFRA) | Successful Target | ||||
UniProt ID | PGFRA_HUMAN | |||||
Gene Name | PDGFRA | |||||
Synonyms |
RHEPDGFRA; Platelet-derived growth factor receptor 2; Platelet-derived growth factor alpha receptor; PDGFR2; PDGFR-alpha; PDGFR-2; PDGF-R-alpha; CD140a antigen; CD140a; CD140 antigen-like family member A; Alpha-type platelet-derived growth factor receptor; Alpha platelet-derived growth factor receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | Platelet-derived growth factor receptor beta (PDGFRB) | Successful Target | ||||
UniProt ID | PGFRB_HUMAN | |||||
Gene Name | PDGFRB | |||||
Synonyms |
Platelet-derived growth factor receptor 1; PDGFR1; PDGFR-beta; PDGFR-1; PDGFR; PDGF-R-beta; CD140b antigen; CD140b; CD140 antigen-like family member B; Beta-type platelet-derived growth factor receptor; Beta-PDGFR; Beta platelet-derived growth factor receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | Tyrosine-protein kinase SYK (SYK) | Successful Target | ||||
UniProt ID | KSYK_HUMAN | |||||
Gene Name | SYK | |||||
Synonyms |
p72-Syk; Spleen tyrosine kinase
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Angiopoietin 1 receptor (TEK) | Clinical trial Target | ||||
UniProt ID | TIE2_HUMAN | |||||
Gene Name | TEK | |||||
Synonyms |
hTIE2; VMCM1; VMCM; Tyrosine-protein kinase receptor TIE-2; Tyrosine-protein kinase receptor TEK; Tyrosine kinase with Ig and EGF homology domains-2; Tunica interna endothelial cell kinase; TIE2; P140 TEK; Endothelial tyrosine kinase; Endothelial Cell-Specific Receptor TIE-2; CD202b antigen; CD202b
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 = 5 nM | [7] | ||
Co-Target Name | Focal adhesion kinase 1 (FAK) | Clinical trial Target | ||||
UniProt ID | FAK1_HUMAN | |||||
Gene Name | PTK2 | |||||
Synonyms |
pp125FAK; p125FAK; Protein-tyrosine kinase 2; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Focal adhesion kinase-related nonkinase; FRNK; FAK1; FADK 1; FADK
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 17 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 17 nM | [1] | ||
3 | Entrectinib | Drug Info | IC50 = 140 nM | [11] | ||
Co-Target Name | Tyrosine-protein kinase Mer (MERTK) | Clinical trial Target | ||||
UniProt ID | MERTK_HUMAN | |||||
Gene Name | MERTK | |||||
Synonyms |
Receptor tyrosine kinase MerTK; Proto-oncogene c-Mer
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 100 nM | [20] | ||
Co-Target Name | Tyrosine-protein kinase BRK (PTK6) | Clinical trial Target | ||||
UniProt ID | PTK6_HUMAN | |||||
Gene Name | PTK6 | |||||
Synonyms |
Protein-tyrosine kinase 6; Breast tumor kinase; BRK
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 = 195 nM | [11] | ||
Co-Target Name | Aurora kinase A (AURKA) | Clinical trial Target | ||||
UniProt ID | AURKA_HUMAN | |||||
Gene Name | AURKA | |||||
Synonyms |
hARK1; Serine/threonine-protein kinase aurora-A; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase 15; Serine/threonine kinase 15; STK6; STK15; IAK1; Breast tumor-amplified kinase; BTAK; Aurora/IPL1-related kinase 1; Aurora-related kinase 1; Aurora-A; Aurora 2; AYK1; AURA; ARK1; ARK-1; AIRK1; AIK
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 = 215 nM | [11] | ||
Co-Target Name | Macrophage-stimulating protein receptor (RON) | Clinical trial Target | ||||
UniProt ID | RON_HUMAN | |||||
Gene Name | MST1R | |||||
Synonyms |
p185Ron; Proteintyrosine kinase 8; Macrophagestimulating protein receptor beta chain; Macrophagestimulating protein receptor; MST1R; MSP receptor; CDw136; CD136
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 = 300 nM | [21] | ||
Co-Target Name | Fibroblast growth factor receptor 3 (FGFR3) | Clinical trial Target | ||||
UniProt ID | FGFR3_HUMAN | |||||
Gene Name | FGFR3 | |||||
Synonyms |
JTK4; FGFR-3; CD333
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | IC50 = 430 nM | [13] | ||
Co-Target Name | Tyrosine-protein kinase Lyn (JTK8) | Clinical trial Target | ||||
UniProt ID | LYN_HUMAN | |||||
Gene Name | LYN | |||||
Synonyms |
p56Lyn; p53Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; Lck/Yes-related novel protein tyrosine kinase
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | IC50 = 840 nM | [13] | ||
Co-Target Name | Fibroblast growth factor receptor 4 (FGFR4) | Clinical trial Target | ||||
UniProt ID | FGFR4_HUMAN | |||||
Gene Name | FGFR4 | |||||
Synonyms |
TKF; JTK2; FGFR-4; CD334
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | IC50 = 950 nM | [13] | ||
Co-Target Name | Ephrin type-A receptor 2 (EPHA2) | Clinical trial Target | ||||
UniProt ID | EPHA2_HUMAN | |||||
Gene Name | EPHA2 | |||||
Synonyms |
Tyrosine-protein kinase receptor ECK; Epithelial cell kinase; EphA2receptor; ECK
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | Vascular endothelial growth factor receptor 1 (FLT-1) | Clinical trial Target | ||||
UniProt ID | VGFR1_HUMAN | |||||
Gene Name | FLT1 | |||||
Synonyms |
Vascular permeability factor receptor; VEGFR1; VEGFR-1; VEGF-1 receptor; Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase FRT; Fms-like tyrosine kinase 1; FRT; FLT
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 1000 nM | [20] | ||
Co-Target Name | Vascular endothelial growth factor receptor 3 (FLT-4) | Clinical trial Target | ||||
UniProt ID | VGFR3_HUMAN | |||||
Gene Name | FLT4 | |||||
Synonyms |
VEGFR3; VEGFR-3; VEGF-3 receptor; Tyrosine-protein kinase receptor FLT4; Fms-like tyrosine kinase 4
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Protein kinase C beta (PRKCB) | Clinical trial Target | ||||
UniProt ID | KPCB_HUMAN | |||||
Gene Name | PRKCB | |||||
Synonyms |
Protein kinase C beta type; PRKCB1; PKCB; PKC-beta; PKC-B
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Aurora kinase B (AURKB) | Clinical trial Target | ||||
UniProt ID | AURKB_HUMAN | |||||
Gene Name | AURKB | |||||
Synonyms |
Serine/threonine-protein kinase aurora-B; Serine/threonine-protein kinase 5; Serine/threonine-protein kinase 12; Serine/threonine protein kinase 12; STK5; STK12; Aurora/IPL1-related kinase 2; Aurora-related kinase 2; Aurora-B; Aurora-2 kinase; Aurora-2; Aurora- and Ipl1-like midbody-associated protein 1; Aurora 1; ARK2; ARK-2; AIRK2; AIM1; AIM-1; AIK2
Click to Show/Hide
|
|||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] | ||
Co-Target Name | Activated CDC42 kinase 1 (ACK-1) | Patented-recorded Target | ||||
UniProt ID | ACK1_HUMAN | |||||
Gene Name | TNK2 | |||||
Synonyms |
Tyrosine kinase non-receptor protein 2; ACK1; ACK-1
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 17 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 17 nM | [1] | ||
3 | Entrectinib | Drug Info | IC50 = 70 nM | [11] | ||
Co-Target Name | TYRO3 tyrosine kinase receptor (TYRO3) | Patented-recorded Target | ||||
UniProt ID | TYRO3_HUMAN | |||||
Gene Name | TYRO3 | |||||
Synonyms |
Tyrosine-protein kinase receptor TYRO3; Tyrosine-protein kinase TIF; Tyrosine-protein kinase SKY; Tyrosine-protein kinase RSE; Tyrosine-protein kinase DTK; Tyrosine-protein kinase BYK; TIF; SKY; RSE; DTK; BYK
Click to Show/Hide
|
|||||
Representative Drug(s) | Crizotinib | Drug Info | IC50 ~ 100 nM | [20] | ||
Co-Target Name | SRSF protein kinase 1 (SRPK1) | Patented-recorded Target | ||||
UniProt ID | SRPK1_HUMAN | |||||
Gene Name | SRPK1 | |||||
Synonyms |
Serine/arginine-rich protein-specific kinase 1; SR-protein-specific kinase 1; SFRS protein kinase 1
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 195 nM | [22] | |||
Co-Target Name | Leukocyte receptor tyrosine kinase (LTK) | Literature-reported Target | ||||
UniProt ID | LTK_HUMAN | |||||
Gene Name | LTK | |||||
Synonyms |
TYK1; Protein tyrosine kinase 1; Leukocyte tyrosine kinase receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 2.7 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 2.7 nM | [1] | ||
Co-Target Name | Proto-oncogene c-Fer (FER) | Literature-reported Target | ||||
UniProt ID | FER_HUMAN | |||||
Gene Name | FER | |||||
Synonyms |
p94-Fer; Tyrosine-protein kinase Fer; Tyrosine kinase 3; TYK3; Fujinami poultry sarcoma/Feline sarcoma-related protein Fer; Feline encephalitis virus-related kinase FER
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 3.3 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 3.3 nM | [1] | ||
Co-Target Name | Proto-oncogene c-Fes (FES) | Literature-reported Target | ||||
UniProt ID | FES_HUMAN | |||||
Gene Name | FES | |||||
Synonyms |
p93c-fes; Tyrosine-protein kinase Fes/Fps; Proto-oncogene c-Fps; Feline sarcoma/Fujinami avian sarcoma oncogene homolog; FPS
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 6 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 6 nM | [1] | ||
Co-Target Name | Focal adhesion kinase 2 (PTK2B) | Literature-reported Target | ||||
UniProt ID | FAK2_HUMAN | |||||
Gene Name | PTK2B | |||||
Synonyms |
Related adhesion focal tyrosine kinase; RAFTK; Protein-tyrosine kinase 2-beta; Proline-rich tyrosine kinase 2; PYK2; FAK2; FADK 2; Cell adhesion kinase beta; Calcium-regulated non-receptor proline-rich tyrosine kinase; Calcium-dependent tyrosine kinase; CAKB; CAK-beta; CADTK
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 14 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 14 nM | [1] | ||
Co-Target Name | Testis-specific serine/threonine-protein kinase 1 (TSSK1B) | Co-Target | ||||
UniProt ID | TSSK1_HUMAN | |||||
Gene Name | TSSK1B | |||||
Synonyms |
TSK-1; TSK1; TSSK-1; Testis-specific kinase 1; Serine/threonine-protein kinase 22A
Click to Show/Hide
|
|||||
Representative Drug(s) | Ceritinib | Drug Info | IC50 = 23 nM | [13] | ||
Co-Target Name | Tyrosine-protein kinase FRK (FRK) | Co-Target | ||||
UniProt ID | FRK_HUMAN | |||||
Gene Name | FRK | |||||
Synonyms |
FYN-related kinase; Nuclear tyrosine protein kinase RAK; Protein-tyrosine kinase 5
Click to Show/Hide
|
|||||
Representative Drug(s) | PF-06463922 | Drug Info | IC50 = 53 nM | Click to Show More | [1] | |
2 | Lorlatinib | Drug Info | IC50 = 53 nM | [1] | ||
Co-Target Name | Cyclin dependent kinase 2-Cyclin A2 complex (CDK2-CCNA2) | Co-Target | ||||
UniProt ID | CDK2_HUMAN-CCNA2_HUMAN | |||||
Gene Name | CDK2-CCNA2 | |||||
Representative Drug(s) | Entrectinib | Drug Info | IC50 ~ 1000 nM | [11] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014 Jun 12;57(11):4720-44. | ||||
REF 2 | Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA). Bioorg Med Chem Lett. 2019 Oct 1;29(19):126624. | ||||
REF 3 | Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. J Med Chem. 2019 Feb 28;62(4):1731-1760. | ||||
REF 4 | First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. Eur J Med Chem. 2017 Jul 7;134:348-56. | ||||
REF 5 | Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2019 Dec 26;62(24):10927-10954. | ||||
REF 6 | Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors. Bioorg Med Chem Lett. 2013 Apr 15;23(8):2408-13. | ||||
REF 7 | Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. | ||||
REF 8 | Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer. J Nat Prod. 2019 Nov 22;82(11):3065-3073. | ||||
REF 9 | Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors. Eur J Med Chem. 2015 Jan 27;90:195-208. | ||||
REF 10 | Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 May 26;59(10):4948-64. | ||||
REF 11 | Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. J Med Chem. 2016 Apr 14;59(7):3392-408. | ||||
REF 12 | An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core. Eur J Med Chem. 2016 Aug 8;118:244-9. | ||||
REF 13 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. | ||||
REF 14 | Discovery of a potent dual ALK and EGFR T790M inhibitor. Eur J Med Chem. 2017 Aug 18;136:497-510. | ||||
REF 15 | Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1507-1513. | ||||
REF 16 | Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2. Eur J Med Chem. 2019 Feb 15;164:193-213. | ||||
REF 17 | The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem. 2012 Jul 26;55(14):6523-40. | ||||
REF 18 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. Bioorg Med Chem. 2019 Oct 15;27(20):115051. | ||||
REF 19 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. Eur J Med Chem. 2019 Jun 1;171:297-309. | ||||
REF 20 | Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase. Eur J Med Chem. 2016 Jan 27;108:322-33. | ||||
REF 21 | Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. | ||||
REF 22 | Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. J Med Chem. 2019 Jun 27;62(12):5673-5724. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.